Impurity

Euro Manganese Produces High-Purity Manganese Sulphate from Chvaletice Demonstration Plant

Retrieved on: 
Monday, November 13, 2023

Euro Manganese’s Demonstration Plant is an essential step in reducing risk in the Company’s flowsheet (see Figure 1).

Key Points: 
  • Euro Manganese’s Demonstration Plant is an essential step in reducing risk in the Company’s flowsheet (see Figure 1).
  • The Demonstration Plant has already provided many learning opportunities and lessons that are being fed into the engineering process for the commercial plant.
  • Dr. Matthew James, President & CEO of Euro Manganese, commented:
    “Producing high-purity manganese sulphate from our Demonstration Plant is a significant milestone for the Company.
  • Euro Manganese continues to demonstrate it is a leader in developing western high-purity manganese processing capacity.

Advent Technologies Reports Q1 2023 Results

Retrieved on: 
Monday, May 15, 2023

Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent” or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced consolidated financial results for the three months ended March 31, 2023.

Key Points: 
  • Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent” or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced consolidated financial results for the three months ended March 31, 2023.
  • The focus towards the mobility sector and stationary power sector has been endorsed by significant opportunity wins for Advent,” said Dr. Vasilis Gregoriou, Chairman and CEO of Advent Technologies.
  • Hood Park R&D and Manufacturing Facility: On March 6, 2023, Advent announced that it opened its new R&D and manufacturing facility at Hood Park in Boston, Massachusetts.
  • Advent intends that its proprietary fuel cell products, such as Serene and Honey Badger 50™, will use the Ion Pair™ Advent MEAs beginning in 2024.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 28, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022.
  • Management will host a conference call Wednesday, March 29, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to discuss its business update and full year 2022 financial results.
  • In December 2022, DiaMedica received written comments from the FDA clarifying its expectations for the design of the in-use study.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year 2022 financial results on Wednesday, March 29, 2023, at 7:00AM Central Time:

Pride and Prejudice Retelling Wins 2021 Award for Fantasy

Retrieved on: 
Monday, January 31, 2022

SAN FRANCISCO, Jan. 31, 2022 /PRNewswire/ -- Retellings of Jane Austen's "Pride and Prejudice" range from Afro-Latino pride to shambling zombies.

Key Points: 
  • SAN FRANCISCO, Jan. 31, 2022 /PRNewswire/ -- Retellings of Jane Austen's "Pride and Prejudice" range from Afro-Latino pride to shambling zombies.
  • Now the novel, published by Acerbic Press, is a 2021 Royal Dragonfly Award Winner for Science Fiction and Fantasy.
  • "I wanted a story that was exciting and romantic, but that showed the social conflict of Regency England," Verant says.
  • Reformer and feminist Mary Shelley published "Frankenstein," a story of moral and technological disruption, only five years after Austen's "Pride and Prejudice."

New Large-Scale Solvent Recycling Plant for Recovery of Large Quantities of Solvents

Retrieved on: 
Tuesday, May 1, 2018

The ASC-3000 separates valuable solvents from impurities such as water or other liquid chemicals by distillation in a highly automated 24-hour operation.

Key Points: 
  • The ASC-3000 separates valuable solvents from impurities such as water or other liquid chemicals by distillation in a highly automated 24-hour operation.
  • A packed column with automatic reflux is used to increase the separation efficiency.
  • The benefit of the plant is that the operator can carry out very economical treatment on his own premises, thereby saving high disposal and transport costs.
  • Depending on the substances or liquids and impurities to be separated, the plant can recover up to 10 tons of liquid recyclable material per day.